Poignard P - Search Results

1

Protection against high-dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody-like molecule CD4-IgG2.

Poignard P, Moldt B, Maloveste K, Campos N, Olson WC, Rakasz E, Watkins DI, Burton DR. Poignard P, et al. PLoS One. 2012;7(7):e42209. doi: 10.1371/journal.pone.0042209. Epub 2012 Jul 27. PLoS One. 2012. PMID: 22848744 Free PMC article.

2

Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design.

Parren PW, Gauduin MC, Koup RA, Poignard P, Fisicaro P, Burton DR, Sattentau QJ. Parren PW, et al. Among authors: poignard p. Immunol Lett. 1997 Jun 1;57(1-3):105-12. doi: 10.1016/s0165-2478(97)00043-6. Immunol Lett. 1997. Corrected and republished in: Immunol Lett. 1997 Jul;58(2):125-32. doi: 10.1016/s0165-2478(97)00109-0 PMID: 9232434 Corrected and republished. Review.

3

Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design".

Parren PW, Gauduin MC, Koup RA, Poignard P, Sattentau QJ, Fisicaro P, Burton DR. Parren PW, et al. Among authors: poignard p. Immunol Lett. 1997 Jul;58(2):125-32. doi: 10.1016/s0165-2478(97)00109-0. Immunol Lett. 1997. PMID: 9271324 Review.

4

Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines.

Sakurai H, Williamson RA, Crowe JE, Beeler JA, Poignard P, Bastidas RB, Chanock RM, Burton DR. Sakurai H, et al. Among authors: poignard p. J Virol. 1999 Apr;73(4):2956-62. doi: 10.1128/JVI.73.4.2956-2962.1999. J Virol. 1999. PMID: 10074145 Free PMC article.

5

Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H, Parren PW, Mosier DE, Burton DR. Poignard P, et al. Immunity. 1999 Apr;10(4):431-8. doi: 10.1016/s1074-7613(00)80043-6. Immunity. 1999. PMID: 10229186 Free article.

6

Antibodies in human infectious disease.

Parren PW, Poignard P, Ditzel HJ, Williamson RA, Burton DR. Parren PW, et al. Among authors: poignard p. Immunol Res. 2000;21(2-3):265-78. doi: 10.1385/IR:21:2-3:265. Immunol Res. 2000. PMID: 10852127 Review.

7

gp120: Biologic aspects of structural features.

Poignard P, Saphire EO, Parren PW, Burton DR. Poignard P, et al. Annu Rev Immunol. 2001;19:253-74. doi: 10.1146/annurev.immunol.19.1.253. Annu Rev Immunol. 2001. PMID: 11244037

8

Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

Zwick MB, Wang M, Poignard P, Stiegler G, Katinger H, Burton DR, Parren PW. Zwick MB, et al. Among authors: poignard p. J Virol. 2001 Dec;75(24):12198-208. doi: 10.1128/JVI.75.24.12198-12208.2001. J Virol. 2001. PMID: 11711611 Free PMC article.

9

Characterization of human immunodeficiency virus type 1 (HIV-1) Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor following in vitro immunization.

Venturini S, Mosier DE, Burton DR, Poignard P. Venturini S, et al. Among authors: poignard p. J Virol. 2002 Jul;76(14):6987-99. doi: 10.1128/jvi.76.14.6987-6999.2002. J Virol. 2002. PMID: 12072499 Free PMC article.

10

Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.

Poignard P, Moulard M, Golez E, Vivona V, Franti M, Venturini S, Wang M, Parren PW, Burton DR. Poignard P, et al. J Virol. 2003 Jan;77(1):353-65. doi: 10.1128/jvi.77.1.353-365.2003. J Virol. 2003. PMID: 12477840 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

107 results

Search Page

Filters